Study of the chronic toxicities of anticancer treatments in patients with localized breast cancer under the age of 45 – cognitive aspect and ancillary study imaging.
Coordinator: Lange M
There are many mechanisms potentially involved in these cognitive disorders (direct toxicity of chemotherapy, concomitant treatments, anxiety-depressive disorders, fatigue, hormonal status, physiological parameters, presence of genetic polymorphisms, etc.), however, they are not fully understood. In addition to the cognitive behavioral study (neuropsychological tests), the imaging study will provide additional information on the anatomical correlates of the cognitive disorders observed in order to better understand their occurrence.
The main objective of this longitudinal study will be to assess the incidence of cognitive impairment and the occurrence of brain abnormalities following anti-cancer treatments in patients under 45 years of age. Several secondary objectives will be studied, such as: evaluating the relationships between cognitive disorders (objective performance and cognitive complaints) and cerebral abnormalities, highlighting the factors that may favor the occurrence of cognitive disorders, etc.
Study methodology: This is a non-randomized, multicentre longitudinal study. The patients will be from the CANTO study cohort. Recruitment = 150 patients (including n=40 with MRI) + 50 healthy subjects.
Current study status: upcoming opening (150 patients and 50 healthy subjects)
Collaboration: Unicancer Promotion
Sponsor: Agence Nationale de la Recherche (ANR)